Jan Pfeiffenberger - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jan Pfeiffenberger

Showing results (41-50 of 45) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 45 results.

Targeted Oncology|February 28, 2024

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World DataAlexander Olkus, Aurelie Tomczak, Anne Katrin Berger, et al.

Orphanet Journal of Rare Diseases|July 4, 2020

The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's diseaseEmilie Glavind, Daniel N Gotthardt, Jan Pfeiffenberger, et al.

British Journal of Cancer|November 1, 2018

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinomaBenjamin Goeppert, Stephanie Roessler, Marcus Renner, et al.

Hepatology (Baltimore, Md.)|September 21, 2018

Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson DiseasePeter Ferenci, Wolfgang Stremmel, Anna Członkowska, et al.

Journal of Hepatology|August 8, 2021

Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)Cornelius Engelmann, Adam Herber, Annegret Franke, et al.

Pageof 5

Search research articles

Showing results (41-50 of 45) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 45 results.

Targeted Oncology|February 28, 2024

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World DataAlexander Olkus, Aurelie Tomczak, Anne Katrin Berger, et al.

Orphanet Journal of Rare Diseases|July 4, 2020

The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's diseaseEmilie Glavind, Daniel N Gotthardt, Jan Pfeiffenberger, et al.

British Journal of Cancer|November 1, 2018

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinomaBenjamin Goeppert, Stephanie Roessler, Marcus Renner, et al.

Hepatology (Baltimore, Md.)|September 21, 2018

Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson DiseasePeter Ferenci, Wolfgang Stremmel, Anna Członkowska, et al.

Journal of Hepatology|August 8, 2021

Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)Cornelius Engelmann, Adam Herber, Annegret Franke, et al.

Pageof 5